Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at Jefferies Group boosted their FY2017 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research note issued on Monday, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of ($5.39) per share for the year, up from their prior forecast of ($5.49). Jefferies Group currently has a “Buy” rating and a $130.00 price target on the stock. Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.32) EPS, FY2018 earnings at ($5.70) EPS, FY2019 earnings at ($3.91) EPS, FY2020 earnings at ($1.71) EPS and FY2021 earnings at $1.41 EPS.
ALNY has been the subject of a number of other reports. Credit Suisse Group lifted their price objective on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Piper Jaffray Companies reissued an “overweight” rating and set a $14.71 price objective (down from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. B. Riley initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price objective for the company. Goldman Sachs Group raised Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Finally, FBR & Co initiated coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $150.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $121.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period last year, the business earned ($1.21) earnings per share.
In related news, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 274,075 shares of company stock valued at $35,356,089. Corporate insiders own 4.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of ALNY. FMR LLC grew its position in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after buying an additional 815,270 shares during the period. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after buying an additional 759,295 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $53,226,000. Orbimed Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 69.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares during the period. Finally, BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 9.3% during the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after buying an additional 441,957 shares during the period. Institutional investors own 88.39% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.